CTEC:LSEConvaTec Group Plc Analysis
Data as of 2026-03-11 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Convatec is trading at ~236 GBp, well above its DCF fair value of ~114 GBp, giving it an **overvalued** price tag despite a solid 7% revenue growth and a forward P/E of ~14. The stock shows a neutral price trend (20‑day SMA 238.8 vs 50‑day SMA 235.8) and a bearish MACD divergence, while volatility remains high at ~41% over the past 30 days. Recent earnings released a lower FY25 profit but the company raised its medium‑term growth outlook, prompting an 8% share price rally and a higher dividend payout (2.21% yield with a 78% payout ratio). However, the balance sheet is heavily leveraged (debt‑to‑equity ~100%) and cash reserves are modest, raising questions about dividend sustainability.
Market Outlook
Short Term
< 1 yearKey Factors
- Bearish MACD histogram and neutral SMA crossover suggest limited upside in the near term
- High short‑term volatility (~41% 30‑day) could amplify price swings
- Upcoming ex‑dividend date (16 Apr) may attract dividend‑seeking investors temporarily
Medium Term
1–3 yearsKey Factors
- Management raised medium‑term revenue guidance, indicating accelerating growth
- Forward P/E of ~14 implies earnings are catching up to price
- Increasing volume trend supports better market participation
Long Term
> 3 yearsKey Factors
- Fundamentals show solid margins and recurring demand for chronic‑care products
- Elevated debt load (DE ratio ~100%) and a price‑to‑book of >400 raise valuation concerns
- Long‑term dividend sustainability is questionable given high payout ratio and limited cash
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.